State Street Corp Has $76.36 Million Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

State Street Corp grew its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 3.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 822,085 shares of the medical instruments supplier's stock after purchasing an additional 28,525 shares during the quarter. State Street Corp owned about 3.66% of LeMaitre Vascular worth $76,363,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in LMAT. Stifel Financial Corp increased its position in LeMaitre Vascular by 10.8% during the third quarter. Stifel Financial Corp now owns 72,194 shares of the medical instruments supplier's stock worth $6,706,000 after acquiring an additional 7,060 shares during the period. Quadrature Capital Ltd acquired a new stake in LeMaitre Vascular in the 3rd quarter worth $281,000. Verition Fund Management LLC bought a new position in shares of LeMaitre Vascular during the 3rd quarter worth about $415,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of LeMaitre Vascular by 98.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,129 shares of the medical instruments supplier's stock valued at $569,000 after buying an additional 3,036 shares during the last quarter. Finally, Glenmede Trust Co. NA lifted its stake in shares of LeMaitre Vascular by 1.3% in the third quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier's stock valued at $976,000 after buying an additional 136 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $90.93 on Wednesday. The firm has a market capitalization of $2.04 billion, a P/E ratio of 49.69, a P/E/G ratio of 2.47 and a beta of 0.93. The stock has a fifty day moving average price of $97.71 and a two-hundred day moving average price of $89.80. LeMaitre Vascular, Inc. has a 52-week low of $52.88 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to analysts' expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm's revenue for the quarter was up 15.6% on a year-over-year basis. During the same quarter last year, the company posted $0.33 EPS. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular's payout ratio is currently 34.97%.

Analyst Ratings Changes

Several equities analysts recently issued reports on LMAT shares. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Oppenheimer restated an "outperform" rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target on the stock. Finally, JMP Securities increased their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 20th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $94.57.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.